WO2004037166A2 - Guanidines therapeutiques - Google Patents

Guanidines therapeutiques Download PDF

Info

Publication number
WO2004037166A2
WO2004037166A2 PCT/US2003/028950 US0328950W WO2004037166A2 WO 2004037166 A2 WO2004037166 A2 WO 2004037166A2 US 0328950 W US0328950 W US 0328950W WO 2004037166 A2 WO2004037166 A2 WO 2004037166A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
cycloalkyl
independently
heteroaryl
Prior art date
Application number
PCT/US2003/028950
Other languages
English (en)
Other versions
WO2004037166A3 (fr
Inventor
Elizabeth Anne Jefferson
Punit Seth
Dale E. Robinson, Jr.
Michael Todd Migawa
Richard H. Griffey
Eric Edward Swayze
Original Assignee
Isis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals, Inc. filed Critical Isis Pharmaceuticals, Inc.
Priority to AU2003298582A priority Critical patent/AU2003298582A1/en
Publication of WO2004037166A2 publication Critical patent/WO2004037166A2/fr
Publication of WO2004037166A3 publication Critical patent/WO2004037166A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne en partie des dérivés de guanidine représentés par la formule (I) ou des formes de sel de ceux-ci qui répondent aux normes pharmaceutiques, des compositions de ces composés et des utilisations de ceux-ci associées, par exemple, à l'inhibition de la traduction induite par IRES. Cette invention concerne aussi le traitement d'infections virales ou d'autres infections.
PCT/US2003/028950 2002-09-17 2003-09-16 Guanidines therapeutiques WO2004037166A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003298582A AU2003298582A1 (en) 2002-09-17 2003-09-16 Therapeutic guanidines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41159802P 2002-09-17 2002-09-17
US60/411,598 2002-09-17

Publications (2)

Publication Number Publication Date
WO2004037166A2 true WO2004037166A2 (fr) 2004-05-06
WO2004037166A3 WO2004037166A3 (fr) 2005-01-06

Family

ID=32176445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028950 WO2004037166A2 (fr) 2002-09-17 2003-09-16 Guanidines therapeutiques

Country Status (2)

Country Link
AU (1) AU2003298582A1 (fr)
WO (1) WO2004037166A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006225394A (ja) * 2004-05-18 2006-08-31 Achillion Pharmaceuticals Inc 置換されたアリールアシルチオ尿素および関連化合物；ウイルス複製のインヒビター
WO2007022964A2 (fr) * 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Composes guanidine a substitution hetaryl et utilisation en tant que partenaires de liaison pour des recepteurs de 5-ht5
WO2010022125A1 (fr) * 2008-08-20 2010-02-25 Schering Corporation Dérivés de pyridine et de pyrimidine à substitution éthylyle et leur utilisation dans le traitement d’infections virales
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8715638B2 (en) 2008-08-20 2014-05-06 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2569019A4 (fr) * 2010-05-11 2015-12-02 Lantheus Medical Imaging Inc Compositions, procédés et systèmes pour la synthèse et utilisation d'agents d'imagerie
US9550000B2 (en) 2011-09-09 2017-01-24 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
US10010631B2 (en) 2006-12-26 2018-07-03 Lantheus Medical Imaging, Inc. Ligands for imaging cardiac innervation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880932A (en) * 1983-03-04 1989-11-14 Bayer Aktiengesellschaft Substituted guanidine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880932A (en) * 1983-03-04 1989-11-14 Bayer Aktiengesellschaft Substituted guanidine derivatives

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006225394A (ja) * 2004-05-18 2006-08-31 Achillion Pharmaceuticals Inc 置換されたアリールアシルチオ尿素および関連化合物；ウイルス複製のインヒビター
WO2007022964A2 (fr) * 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Composes guanidine a substitution hetaryl et utilisation en tant que partenaires de liaison pour des recepteurs de 5-ht5
WO2007022964A3 (fr) * 2005-08-24 2007-05-31 Abbott Gmbh & Co Kg Composes guanidine a substitution hetaryl et utilisation en tant que partenaires de liaison pour des recepteurs de 5-ht5
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
US11241509B2 (en) 2006-12-26 2022-02-08 Lantheus Medical Imaging, Inc. Ligands for imaging cardiac innervation
US10010631B2 (en) 2006-12-26 2018-07-03 Lantheus Medical Imaging, Inc. Ligands for imaging cardiac innervation
US8715638B2 (en) 2008-08-20 2014-05-06 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8541434B2 (en) 2008-08-20 2013-09-24 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP2012500279A (ja) * 2008-08-20 2012-01-05 シェーリング コーポレイション エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
WO2010022125A1 (fr) * 2008-08-20 2010-02-25 Schering Corporation Dérivés de pyridine et de pyrimidine à substitution éthylyle et leur utilisation dans le traitement d’infections virales
EP2569019A4 (fr) * 2010-05-11 2015-12-02 Lantheus Medical Imaging Inc Compositions, procédés et systèmes pour la synthèse et utilisation d'agents d'imagerie
US9682927B2 (en) 2010-05-11 2017-06-20 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
RU2710736C2 (ru) * 2010-05-11 2020-01-10 Лантеус Медикал Имэджинг, Инк. Композиции, способы и системы для синтеза и применение визуализирующих средств
US11174223B2 (en) 2010-05-11 2021-11-16 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
US9550000B2 (en) 2011-09-09 2017-01-24 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents

Also Published As

Publication number Publication date
WO2004037166A3 (fr) 2005-01-06
AU2003298582A8 (en) 2004-05-13
AU2003298582A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
US10556904B2 (en) Derivatives and methods of treating hepatitis B infections
CS413791A3 (en) Pyrrole-amidine antitumor preparations
US20050250707A1 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
EP3898628A1 (fr) Dérivés d'hétéroaryldihydropyrimidine et procédés de traitement d'infections par le virus de l'hépatite b
AU2002345644A1 (en) HV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
SK2082002A3 (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
SK279058B6 (sk) Substituovaný n-[(2-morfolynyl)alkyl]banzamidový d
KR101414778B1 (ko) 페닐피리미돈을 함유하는 화합물, 그 약물 조성물 및 그 제조방법과 용도
BR112015017963B1 (pt) Composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
RU2099323C1 (ru) Производные гуанидина, способ их получения и фармацевтическая композиция, обладающая гипогликемической активностью
JP7408819B2 (ja) イソインドリン誘導体、並びにその医薬組成物及び使用
WO2020089459A1 (fr) Nouvelles 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines d'urée actives contre le virus de l'hépatite b (vhb)
WO2004037166A2 (fr) Guanidines therapeutiques
EP3068778A2 (fr) Inhibiteurs hsp90 à base de coumarine à substituants d'urée et d'éther
WO2007133211A1 (fr) Composés de quinolone et coumarine 3,4-disubstitués
CN110590708B (zh) 芳酰基哌嗪类化合物及其制备方法和在抗病毒中的应用
KR19990045727A (ko) 선택적 β３ 아드레날린 효능제
CN109574920B (zh) 3-腈基-6环丙基吡啶类ido1抑制剂及其用途
WO2020067398A1 (fr) Dérivé de biaryl-sulfonamide ayant une activité inhibitrice contre l'invasion des cellules par un filovirus
NZ241296A (en) Substituted 1,2,4-triazine derivatives and pharmaceutical compositions
TW202045516A (zh) 雙環磺醯胺
CA3178647A1 (fr) Amides tricycliques substitues, analogues de ceux-ci et procedes les mettant en oeuvre
CA2725425A1 (fr) Inhibiteur d'homocysteine synthase
CN101245051B (zh) 2，4-二取代氨基-6-取代-[1，3，5]三嗪类化合物、其制备方法、药物组合物及用途
RU2272807C2 (ru) Новые производные амидинов, их получение и их использование в качестве лекарственных средств

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP